Site Details
LOCATION
University of Washington (Seattle) Harborview Medical Center
Box 359929
325 9th Avenue
Seattle, Washington. 98104
SiteType
CRS
Site Trials
Treatment Experienced
Closed to accrual
A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV
People with HIV can have an increase in inflammation in their body organs even after taking anti-HIV medicines (ART, or antiretroviral therapy). Chronic HIV infection has been associated with a state of systemic inflammation and immune activation, thus increasing the incidence of heart disease and death from heart disease. HIV researchers are studying the harmful effects of this long-term inflammation and possible ways to prevent these complications.
The A5415 study is being conducted to investigate the effects of cenicriviroc (CVC) on arterial inflammation in individuals with HIV on stable suppressive ART. CVC is a medication being developed as a treatment for HIV and being studied as a possible drug to decrease blood vessel inflammation and plaque formation in the setting of chronic infection.
Treatment Naïve
Active, Not Recruiting
A5388: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined with ART Initiation during Acute HIV Infection to Induce HIV Remission
Scientists are looking for ways to minimize the distribution of HIV-1 in the body, especially where anti-HIV medications (ART) are unable to reach. Starting ART as soon as possible following a diagnosis of Acute HIV Infection (AHI) has been shown to better preserve the immune system. Broadly neutralizing antibodies (bNAbs), when administered with ART, also have the potential to prevent the HIV virus from being able to reproduce.
This is a randomized, placebo-controlled research study that will enroll adults with recently diagnosed AHI. All participants will begin ART at entry and receive a single dose of two bNAbs (VRC07-523LS and PGT121.414.LS) or placebos. Everyone will be followed for about 1 year after starting ART, then stop ART for up to 2.5 years, then be followed for 1 year after restarting ART.